Antifungal agent 6 shows antifungal activity.

Compound 24f, an antifungal agent also known as 'Antifungal agent 85,' demonstrates potent antibacterial properties, exhibiting minimum inhibitory concentration (MIC) values ranging from 2.5 to 10 μM against diverse Gram-positive bacteria [1].

Compound 3a (Antifungal agent 62) exhibits potent fungicidal properties, particularly against Fusarium oxysporum f.sp. cucumerinum, and is utilized in antiviral and fungicidal research [1].

Antifungal agent 82 (compound G34) demonstrates outstanding in vitro antifungal efficacy against Valsa mali, exhibiting an EC50 value of 0.57 μg/mL, and has also shown excellent in vivo protective effects at a concentration of 40 μg/mL [1].

Antifungal agent 81(G22) exhibits excellent antifungal properties, demonstrating an in vitro IC50 value of 0.48 mg/L against Valsa mali. Moreover, it also shows robust in vivo protection against V. mali at a concentration of 40 mg/L [1].

Compound 3i (Antifungal agent 63) is a fungicidal agent displaying potent activity against Fusarium oxysporum f.sp. cucumerinum and has applications in antiviral and fungicidal research [1].

Antifungal agent 77 (Compound 13h) exhibits not only antifungal properties, but also effective insecticidal activity against Mythimna separata, Helicoverpa armigera, Ostrinia nubilalis, and Spodoptera frugiperda, with mortality rates of 30%, 25%, 40%, and 25% respectively at a concentration of 500 μg/mL. Additionally, this compound demonstrates toxicity in zebrafish embryos with an LC50 of 2.43 μg/mL [1].

Antifungal agent 75 (compound 6r) effectively combats Candida albicans by substantially inhibiting biofilm formation, enhancing cell membrane permeability, diminishing membrane ergosterol levels, impairing membrane structure, and compromising cell structural integrity, thus demonstrating exceptional antifungal activity [1].

Antifungal agent 68 (compound 10) effectively combats fungal infections caused by Candida and Cryptococcus gattii through the inhibition of ergosterol biosynthesis, likely via interaction with lanosterol 14α-demethylase (CYP51). It is proposed that the imidazole ring of antifungal agent 68 interacts with the heme group of CYP51 [1].

Antifungal agent 50 exhibits minimum inhibitory concentrations (MICs) ranging from less than 0.063 to 1 μg/mL [1].

Antifungal agent 73 (compound A32) effectively combats azole-resistant candidiasis by disrupting the fungal cell wall and membrane. It demonstrates potent in vivo activity against pathogenic fungi, including fluconazole-resistant strains [1].

Compound 9 (Antifungal agent 67), an imidazole class antifungal, exhibits efficacy against Candida and possesses a CC50 value of 33.6 μM in neonatal rat cardiomyoblasts [1].

Antifungal Agent 61 (Compound 38) is an antifungal agent that inhibits V. mali, with an EC50 value of 0.50 mg/L. This compound impedes V. mali's growth by inducing cell deformation and contraction, diminishing intracellular mitochondrial count, thickening the cell wall, and enhancing cell membrane permeability [1].

Antifungal agent 25 is an effective, broad-spectrum, metabolically stable antifungal agent in vivo. antifungal agent 25 exhibits antifungal effects against both Candida albicans and fluconazole-resistant Candida albicans.

Antifungal Agent 29 (compound 9d) is a potent, selective, and non-toxic agent effective against Cryptococcus neoformans, exhibiting an MIC of ≤0.23 μM [1].

Pradimicin A derivative 26 exhibits antifungal, antiviral, and antiparasitic properties by attaching to d-mannose (Man)-rich glycans in pathogenic organisms [1].

Antifungal agent 54 (compound A05) serves as a potent inhibitor against Fluconazole-resistant strains, outperforming Miconazole in efficacy. It exhibits considerable activity against Candida albicans, with minimum inhibitory concentration (MIC) values ranging from 0.25-1 μg/mL [1].

Antifungal agent 51 (5c) exhibits potent antifungal activity against Candida albicans FDC 151, Candida parapsilosis ATCC 22019, and Candida tropicalis FDC 138, with a minimum inhibitory concentration (MIC) value of less than 0.063 μg/mL. It demonstrates low toxicity to cells and no carcinogenicity [1].

Antifungal agent 17 showed good antifungal activity against B. cinerea (EC50: 2.86 μg/mL).

Antifungal agent 28 (compound 18) is a selective and potent antifungal agent that disrupts mature Candida biofilms and inhibits pathogenic strains of Candida albicans and non-Candida albicans, including fluconazole-resistant strains. Inhibitory effect.

Antifungal agent 33 (compound 4e) is a potent antifungal agent with significant antifungal activity against Candida albicans (MIC: 16 μg/ml). (IC50: 0.19 μg/ml).

Antifungal agent 24 (Compound 6) is an antifungal agent that inhibits Candida albicans (MIC: 0.03 μg/ml).

Antifungal agent 19 shows the potent antifungal activity ( EC 50 = 0.72 μM).

Antifungal agent 72 (Compound B8) demonstrates potent activity by inhibiting the efflux pump function and downregulating resistance-associated genes via disruption of the Pdr1-KIX interaction (K i : 11.7 μM). It exhibits efficacy against Fluconazole-resistant strains, evidenced by a MIC of 63 ng/mL, and displays synergistic effects when combined with Fluconazole. This compound is particularly useful for researching C. glabrata infections [1].

Antifungal agent 78 (compound 25am) exhibits potent activity, with an EC50 of 13.46 μM against Fusarium graminearum [1].

Antifungal agent 48 (Example 308), active against Cryptococcus neoformans, exhibits a minimum inhibitory concentration (MIC) value of 11 μM [1].

Antifungal agent 76 has broad-spectrum antifungal activity with a MIC value of 0.25-16 μg/mL.Antifungal agent 76 may act by disrupting fungal cell membranes and can be used to study fungal infections.

Antifungal agent 35 is an effective antifungal agent that potentiates the antifungal activity of fluconazole against C. albicans.

Antifungal agent 40 is an antifungal agent that extends into the narrow hydrophobic pocket II of C. alb. CYP51 and inhibits the activity of lanosterol 14α-demethylase (CYP51), which has an inhibitory effect on biofilm formation.

Antifungal agent 31 is an orally active, triazole antifungal agent possessing a pyrrolizinone scaffold that exhibits some antifungal activity against Candida and filamentous fungi.Antifungal agent 31 significantly reduced mortality and renal fungal burden in two mouse models of lethal systemic infection.

Antifungal agent 20 demonstrates significant antifungal efficacy against a range of fungal pathogens including Colletotrichum gloeosprioides, Rhizoctonia solani, Phytophthora nicotianae var. nicotianae, Diplodia pinea, Colletotrichum acutatum, and Fusarium oxysporum f. sp. niveum.

Antibacterial Agent 84, an antifungal compound, effectively inhibits candidiasis through a CNB1-dependent mechanism and reduces the viability of the C. albicans biofilm [1].

Antifungal agent 58 (compound A21) exhibits high potency against Fluconazole-resistant strains and outperforms Miconazole in effectiveness. It inhibits Candida albicans strains with minimum inhibitory concentration (MIC) values ranging from 0.06 to 8 μg/mL [1].

Antifungal agent 47 (compound 3b) exhibits the most potent and broad-spectrum fungicidal properties, including significant inhibition of respiration and adenosine 5′-triphosphate synthesis, showcasing its potential as an effective fungicide [1].

Antifungal agent 15 exhibits remarkable potency, with EC50 values of 0.52 and 0.50 μg/mL against S. sclerotiorum and B. cinerea, respectively.

Antifungal agent 69 (compound 13), a eugenol-imidazole derivative, demonstrates targeted activity against Candida albicans with a minimum inhibitory concentration (MIC) of 4.6 μM, while exhibiting negligible cytotoxicity. This compound disrupts ergosterol biosynthesis, contributing to its antifungal efficacy [1].

Antifungal agent 66 (compound 10) exhibits broad-spectrum antifungal activity against seven phytopathogenic fungal mycelia and significant inhibitory effects on the spores of B. cinerea, with an IC50 value of 47.7 μg/mL [1].

Antifungal agent 16 has antimicrobial activity comparable to that of ciprofloxacin and has higher antifungal activity than fluconazole.

Antifungal agent 11 has a good antifungal effect.

Antifungal agent 43 is an antifungal agent that exhibits antifungal effect by inhibiting biofilm formation. antifungal agent 43 shows low toxicity to human cancer cell lines.

Antifungal agent 2 is a broad-spectrum fungal inhibitor that inhibits the growth of pertinent species of Cryptococcus, Candida, and Aspergillus at a concentration as low as 0.5 μg/mL.

Antifungal agent 39 (Compound 9h) is a broad-spectrum antifungal agent.

Antifungal agent 18 is a novel antifungal agent for the treatment of fungal infection.

Antifungal agent 56 (compound A09) is a potent antifungal agent, demonstrating superior efficacy against Fluconazole-resistant strains and outperforming Miconazole. It effectively inhibits Candida albicans strains, with minimal inhibitory concentration (MIC) values ranging from 0.03 to 0.25 μg/mL [1].

Antifungal agent 55 (Compound A07) effectively inhibits Fluconazole-resistant strains of Candida albicans, demonstrating greater efficacy than Miconazole. It exhibits minimum inhibitory concentrations (MIC) values ranging from 0.25-1 μg/mL [1].

Antifungal Agent 53 (A03), a potent Candida albicans CYP51 inhibitor, exhibits antifungal activity by preventing fungi biofilm formation and demonstrates good safety [1].

Antifungal agent 30 is a potent antifungal agent that exhibits good antifungal activity against Candida albicans (CPCC400616) (MIC: 0.03 μg/mL) and Aspergillus fumigatus (MIC: 0.5 μg/mL). Antifungal agent 30 exerts antifungal activity through hydrogen and ligand interactions with CYP51.

Antifungal agent 27 (compound 7) is a chemical compound possessing antifungal properties. It exhibits moderate antibacterial activity and weak antifungal activity against MRSA and C. albicans SS5314, with minimal inhibitory concentration (MIC) values of 8 and 32 μg/mL, respectively [1].

Antifungal agent 32 (compound 1a) is a highly effective antifungal compound. It displays strong inhibitory activity against Candida albicans filamentation and biofilm formation, as well as inhibiting the morphological switching of Candida albicans and its adherence to epithelial cells. This makes Antifungal agent 32 a valuable tool for research on Candida albicans infections [1].

Antifungal agent 42 is an antifungal agent that has an inhibitory effect on biofilm formation. Antifungal agent 42 inhibits C.alb.'s lanosterol 14α-demethylase (CYP51).